Evidence map›Paper›PMID 37924213›Full record

ReviewThe neuroradiology journal2024

The T2-FLAIR mismatch sign in oncologic neuroradiology: History, current use, emerging data, and future directions.

Samir A Dagher, Riley Hideo Lochner, Burak Berksu Ozkara, Donald F Schomer, Max Wintermark, Gregory N Fuller, F Eymen Ucisik

Open access · hybridAbstract readReview
In one paragraph

Review in The neuroradiology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Samir A DagherDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-0155-7444
Riley Hideo LochnerSection of Neuropathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1513-328X
Burak Berksu OzkaraDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8769-3342
Donald F SchomerDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8303-6786
Max WintermarkDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6726-3951
Gregory N FullerDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9447-2647
F Eymen UcisikDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6083-7465
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The T2-Fluid-Attenuated Inversion Recovery (T2-FLAIR) mismatch sign is a radiogenomic marker that is easily discernible on preoperative conventional MR imaging. Application of strict criteria (adult population, cerebral hemisphere location, and classic imaging morphology) permits the noninvasive preoperative diagnosis of isocitrate dehydrogenase (IDH)-mutant 1p/19q-non-codeleted diffuse astrocytoma with near-perfect specificity, albeit with variably low sensitivity. This leads to improved preoperative planning and patient counseling. More recent research has shown that the application of less strict criteria compromises the near-perfect specificity of the sign but remains adequate for ruling out IDH-wildtype (glioblastoma) phenotype, which bears a far grimmer prognosis compared to IDH-mutant diffuse astrocytic disease. In this review, we elaborate on the various definitions of the T2-FLAIR mismatch sign present in the literature, illustrate these with images obtained at a comprehensive cancer center, discuss the potential of the mismatch sign for application to certain pediatric-type brain tumors, namely dysembryoplastic neuroepithelial tumor and diffuse midline glioma, and elaborate upon the clinical, histologic, and molecular associations of the T2-FLAIR mismatch sign as recognized to date. Finally, the sign's correlates in diffusion- and perfusion-weighted imaging are presented, and opportunities to further maximize the diagnostic and prognostic applications of the sign in the context of the 2021 revision of the WHO Classification of Central Nervous System Tumors are discussed.

Indexed as

Brain NeoplasmsHumansMagnetic Resonance ImagingNeuroimagingastrocytomagliomaisocitrate dehydrogenaseMRIradiogenomicsT2-FLAIR mismatch

Identifiers

PMID37924213
PMCPMC11366202
OpenAlexW4388342857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.